real-time news and commentary for investors
Monday, Sep 23
Needham still positive on Sarepta as competitive landscape is improved
- Needham is apparently out reiterating a Buy rating on Sarepta Therapeutics (SRPT), price target is $57.
- Chad Messer says "drisapersen's failure may lead to skepticism on the exon-skipping approach in general, [but Needham] remains confident in eteplirsen's efficacy and believes [the drisapersen news] improves the competitive situation."
- See previous coverage